Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph II of PARP inhibition & Anti-PD-L1 Thrpy Either alone or in Combo in HDR Deficient TNBC

Protocol: OSU-17011

Full Title

A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP inhibition (veliparib; ABT-888) and Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) Either alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

Breast Cancer